Molecularly Targeted Agents Have Lower Rates of Severe Diarrhea than Standard Chemotherapy

VBCC - September 2012, Volume 3, No 6 - Health Policy
Phoebe Starr

New York, NY—Diarrhea is a common side effect of standard chemo­therapy, but the risk is less well characterized with molecularly targeted agents, which may add to the risk of diarrhea when combined with standard chemo­therapy, according to Lowell Anthony, MD, Professor of Medicine, University of Kentucky, and Chief of Medical Oncology, UK HealthCare, Lexington, who discussed this topic at the 2012 Multinational Association of Supportive Care in Cancer Inter­national Symposium.

Diarrhea induced by any treatment can increase morbidity and mortality, leading to increased resource utilization and costs of care, if not controlled at the outset, Dr Anthony stated. “Grade 1 and 2 diarrhea can quickly spiral downward to grades 3 and 4 if not controlled, requiring hospitalization and even causing death,” he told listeners. “Only you can really prevent the spiral of diarrhea.”

Diarrhea, especially when it is severe, requires increased healthcare resources to manage sequelae, such as fatigue and malaise, abdominal cramping, incontinence, increased anxiety, perineal pain, malnutrition, weight loss, and immobility.

Chemotherapy-induced diarrhea is seen with 5-fluorouracil, irinotecan, paclitaxel, high-dose epirubicin, and other standard chemotherapies. Mo­lecularly targeted therapies, such as bortezomib, bevacizumab, epidermal growth factor receptor inhibitors, and the multitargeted tyrosine kinase inhibitors sunitinib and sorafenib, also cause diarrhea.

 “Targeted therapies can cause diarrhea, but nowhere near the amount that is associated with irinotecan,” noted Dr Anthony. “With targeted therapy, the only good news is that the rates of serious grade 3 and 4 diarrhea are under 10%, but they do cause grades 1 and 2 diarrhea. In general, treatment delays are not necessary, and we don’t stop treatment.”

Dr Anthony cited the following rates of diarrhea associated with molec­ularly targeted agents that have been reported in various clinical trials:

  • Bortezomib—45%, any grade
  • Cabozantinib—57%, grades 1-4
  • Lapatinib—48%-64%, any grade
  • Regorafenib—32%, grades 1-4
  • Vandetanib—56%, grades 1-4.

Diarrhea is treated in the context of other side effects associated with mo­lecularly targeted agents, Dr Anthony noted, such as peripheral neuropathy or cardiovascular side effects (eg, QTc prolongation, hypertension, and heart failure).

Dr Anthony emphasized the importance of a differential diagnosis and identifying the correct etiology for diarrhea. Etiology can include an in­fection on top of toxic injury, increased motility, or hyperthyroidism, he pointed out. Chemotherapy-induced diarrhea is secretory and continues after patients stop eating.

Risk factors for chemotherapy-induced diarrhea include previous chemotherapy, previous pelvic irradiation, performance status, the presence of chemotherapy-induced diarrhea on a previous treatment cycle, increased age, and female gender.

Three drugs or drug classes are guideline-recommended for chemo­therapy-induced diarrhea, including loperamide, opium derivatives, and octreotide. The treatment of grades 1 or 2 uncomplicated diarrhea entails the ingestion of adequate fluids and dietary intervention with the BRAT (bananas, rice, applesauce, and toast) diet. Patients with grade 3 or 4 diarrhea may require hospitalization, antibiotics, octreotide, and intravenous fluids.

Related Items
FDA Taking Steps to Promote Generic Drug Competition and Improve Patient Access to Therapies
Eileen Koutnik-Fotopoulos
VBCR - April 2018, Vol 7, No 1 published on April 17, 2018 in Health Policy
Medical Groups Applaud Congressional Leaders for Agreement to Repeal Medicare Therapy Caps
Anne Rowe
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Health Policy
ACR Responds to 2019 Benefit and Payment Parameters Proposed Rule
Anne Rowe
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Health Policy
Support Continues to Grow for Step Therapy Reform
Rebecca Bailey
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Health Policy
Use of Conventional Synthetic versus Biologic Disease-Modifying Antirheumatic Drugs May Reduce Costs in Treatment of RA
Leslie Wyatt
VBCR - December 2017, Vol 6, No 5 published on December 19, 2017 in Health Policy
Tocilizumab Demonstrates Success in the Treatment of Patients with Giant Cell Arteritis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Giant Cell Arteritis
Rituximab Maintenance Outshines Azathioprine for Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis
Phoebe Starr
VBCR - December 2016, Vol 5, No 6 published on January 5, 2017 in Vasculitis
Cost of Drugs and Affordability Don’t Always Jibe
Phoebe Starr
VBCC - July 2016, Vol 7, No 6 published on July 13, 2016 in Value in Oncology
Usefulness of Vitamin D Supplementation Questioned in Patients with Knee Osteoarthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Osteoarthritis
Baricitinib Effective in Patients with Refractory Rheumatoid Arthritis
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Rheumatoid Arthritis
Last modified: May 28, 2014
  • Rheumatology Practice Management
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology